- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Antithrombotic Therapy
The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.
AHA/ASA Release Guidance for Treatment of COVID-19 Vaccine-Related Clotting, Low Platelet Counts
May 03, 2021
The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.
Extended-Duration DAPT Reduces Mortality, Event Rate in TWILIGHT-like Patients
April 29, 2021
An SCAI 2021 analysis of more than 4k patients with characteristics similar to those included in the TWILIGHT trial indicates extended-duration DAPT, defined as a duration of more than 12 months post-PCI, was a more efficacious approach than short-term DAPT in this patient population.
A Hidden Hypothesis—Blood Clots and Myocardial Infarction with Arnold Meshkov, MD
March 23, 2021
In this column, Arnold Meshkov, MD, explores the history of the "Thrombus Hypothesis" and his experiences with thrombus in myocardial infarction as a practicing clinician.
Rivaroxaban Noninferior to Warfarin in AFib Patients w/ Bioprosthetic Mitral Valves
November 15, 2020
Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.
CAC Scoring Helps Determine Net Benefit or Harm of Aspirin in Primary Prevention
October 28, 2020
An analysis of the Dallas Heart Study from UTSW details how use of CAC scoring can help determine what patients would stand to benefit from aspirin use for primary prevention.
Analysis Details Use of Antiplatelet Therapy After Peripheral Vascular Interventions
August 21, 2020
An analysis of data from a Society of Vascular Surgeons registry is shedding light on the use of DAPT in patients following peripheral vascular interventions.
DOACs More Effective than Low Molecular Weight Heparin for Recurrent VTE in Cancer Patients
August 13, 2020
A meta-analysis of 4 randomized trials is shedding light on the efficacy and safety of direct oral anticoagulant use for reducing recurrent VTE in patients with cancer.
Meta-Analysis Compares Effects of DAPT Durations After PCI with DES
August 03, 2020
A new network meta-analysis offers an overview of the clinical benefit of less than 6 months, 6-month, 12-month, and extended periods of DAPT therapy after PCI with drug-eluting stents.
Clay Johnston, MD, PhD: Ticagrelor DAPT and THALES Results
July 27, 2020
S. Claiborne Johnston discusses the results of the phase 3 THALES trial examining use of ticagrelor dual antiplatelet therapy for reducing subsequent stroke in patients with AIS or TIA.
Low-Dose Prasugrel Results in Similar Efficacy, Reduced Bleeding vs Ticagrelor
July 21, 2020
A prespecified analysis of ISAR-REACT 5 is shedding light on the effectiveness and safety of age- and weight-adjusted prasugrel versus ticagrelor following ACS.